Overview

A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

Status:
Recruiting

Trial end date:
2021-12-08

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of helicobacter pylori (HP) eradication with bismuth-containing quadruple therapy with vonoprazan versus esomeprazole in all HP-positive participants.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Amoxicillin
Bismuth
Citric Acid
Clarithromycin
Esomeprazole
Potassium Citrate
Sodium Citrate